Breast

Mersana Therapeutics Announces Option Agreement with GSK for the Co-Development and Commercialization of XMT-2056, an Immunosynthen ADC Targeting HER2

Retrieved on: 
Monday, August 8, 2022
U.S. Securities and Exchange Commission, ADC, Risk, Forward-looking statement, GLOBE, Senior, Breast, Technology, Private Securities Litigation Reform Act, SEC, Cancer, MRSN, Clinical trial, GSK, Conference call, HER2, Security (finance), Patient, Review, Therapy, The Boston Globe, COVID-19, Pertuzumab, Sodium-dependent phosphate transport protein 2B, B7-H4, Trastuzumab, Stomach, Safety, Control, NASDAQ, Webcast, Investor, Ovarian cancer, Conference, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Immune system, Pharmaceutical industry, Research

Under the terms of the agreement, Mersana will receive an upfront option purchase fee of $100 million.

Key Points: 
  • Under the terms of the agreement, Mersana will receive an upfront option purchase fee of $100 million.
  • Mersana also is eligible to receive up to $1.36 billion in the form of an option exercise payment and development, regulatory and commercial milestone payments if GSK exercises its option.
  • If it exercises its profit-share option, Mersana will be eligible to receive tiered royalties on net sales outside of the United States.
  • Mersanas earlier stage programs include XMT-1660, a Dolasynthen ADC targeting B7-H4, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2).

Mersana Therapeutics Provides Business Update and Announces Second Quarter 2022 Financial Results

Retrieved on: 
Monday, August 8, 2022
U.S. Securities and Exchange Commission, Exercise, GLOBE, ORR, R, SEC, Clinical trial, GSK, Security (finance), Research, Patient, G&A, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Risk, Breast, Technology, Private Securities Litigation Reform Act, Conference call, Sodium-dependent phosphate transport protein 2B, B7-H4, Safety, Stomach, Janssen, Webcast, Ovarian cancer, Conference, ADC, Forward-looking statement, Carboplatin, HER2, Cancer, Neoplasm, Therapy, The Boston Globe, COVID-19, Maintenance, Investor, FDA, DAR, MRSN, IND, Control, NASDAQ, Platinum, Medical imaging, Fine chemical, Pharmaceutical industry

ET

Key Points: 
  • ET
    CAMBRIDGE, Mass., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today provided a business update and reported financial results for the second quarter ended June 30, 2022.
  • Mersana expects to disclose initial interim dose escalation data in Q4 2022, with a primary focus on safety and tolerability.
  • Collaboration revenue for the second quarter of 2022 was $4.3 million, compared to an immaterial amount for the same period in 2021.
  • ET to discuss business updates and its financial results for the second quarter of 2022.

Panavance Therapeutics Announces Publication of Promising Preclinical Data Evaluating GP-2250 for the Treatment of Malignant Peritoneal Mesothelioma

Retrieved on: 
Monday, August 8, 2022
FDA, Apoptosis, Mesothelioma, Respiration (physiology), CEO, Forward-looking statement, GLOBE, La Trobe Institute for Molecular Science, Population, Breast, Synergy, Cancer, Cisplatin, Flow cytometry, ST, Quality of life, Patient, University of Duisburg-Essen, Therapy, Company, International Journal of Molecular Sciences, Pancreatic cancer, Organ (anatomy), Manuscript, General officer, Canadian International Council, Mitomycin C, Melanoma, University, Ovarian cancer, Ruhr University Bochum, Necrosis, Pharmaceutical industry, Panaveli

BERWYN, Pa., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Panavance Therapeutics Inc. (“Panavance” or the “Company”), a clinical-stage pharmaceutical company advancing the development of a novel oncology therapeutic designed to disrupt cancer’s energy metabolism and improve quality of life for patients, today announced the publication of positive preclinical data from a 3-D in vitro study evaluating GP-2250 for the treatment of malignant peritoneal mesothelioma. The manuscript titled, “Substance GP-2250 as a New Therapeutic Agent for Malignant Peritoneal Mesothelioma—A 3-D In Vitro Study1,” was published in the peer-reviewed journal, International Journal of Molecular Sciences. 

Key Points: 
  • This preclinical study is the first to investigate effects of the novel agent GP-2250 on malignant mesothelioma.
  • As we progress its development for the treatment of pancreatic ductal adenocarcinoma, amassing a growing body of data provides valuable validation and guidance.
  • We look forward to further exploring the potential of GP-2250, commented Greg Bosch, Chairman and CEO of Panavance Therapeutics.
  • GP-2250 showed promising antineoplastic effects on malignant mesothelioma cells in vitro especially in combination with cisplatin/mitomycin C even when used at lower concentrations.

Dr. Micheline Goulart Joins Well-Respected New York Plastic Surgery Practice New You Plastic Surgery

Retrieved on: 
Monday, August 8, 2022
Woman, Ohio State University, Breast, Research, Health, Great Neck, New York, Park Avenue, Patient, Program, Ohio State University Wexner Medical Center, William A. Shine Great Neck South High School, University, Rhinoplasty, Time, Dentistry, Medicine, New York State Route 25A, New

NEW YORK , Aug. 8, 2022 /PRNewswire-PRWeb/ --

Key Points: 
  • Dr. Micheline Goulart has been recognized across the country for her outstanding work in cosmetic and reconstructive facial plastic surgery as well as breast and body contouring procedures.
  • Dr. Goulart is an enterprising leader of a new generation of plastic surgeons, fusing surgical skills with a sophisticated, open-minded approach to patient care.
  • "I am excited to join New You Plastic Surgery and assist in their mission to make both the functional and aesthetic components of plastic surgery accessible and achievable for any and all patients," says Dr. Micheline Goulart.
  • More About New You Plastic Surgery:
    New You Plastic Surgery is the practice of board-certified plastic surgeon Dr. Jeremy Nikfarjam.

Guardant Health and Blueprint Medicines present real-world data identifying EGFR C797X mutation as most common resistance mechanism to osimertinib therapy at IASLC 2022 World Conference on Lung Cancer

Retrieved on: 
Monday, August 8, 2022
Science, Data Analytics, Research, Pharmaceutical, Oncology, Health, Professional Services, Genetics, U.S. Securities and Exchange Commission, MET, Cancer, Security (finance), Research, Annual report, Marketing, Patient, International Association, Emory University, Disease, Multimedia, HIV disease progression rates, Lung cancer, Breast, Nasdaq, Private Securities Litigation Reform Act, BPMC, Analysis, DNA, Data, Safety, Colon, Science, Conference, Winship Cancer Institute, Incidence, NSCLC, COVID-19, Large-cell lung carcinoma, Prostate, Financial condition report, Mutation, Lung, Goal, Helmy Eltoukhy, Result, Genomics, GH, Neoplasm, Twitter, Degenerative disease, EGFR, LinkedIn, Blueprint, FACP, Medical imaging, Pharmaceutical industry

The results are being reported today at the International Association for the Study of Lung Cancer (IASLC) 2022 World Conference on Lung Cancer in Vienna.

Key Points: 
  • The results are being reported today at the International Association for the Study of Lung Cancer (IASLC) 2022 World Conference on Lung Cancer in Vienna.
  • In patients likely to experience disease progression after first-line treatment with osimertinib, the cumulative incidence of EGFR C797X mutations was 12.5 percent.
  • Blueprint Medicines is a global precision therapy company that invents life-changing therapies for people with cancer and blood disorders.
  • Except as required by law, Guardant Health and Blueprint Medicines explicitly disclaim any obligation to update any forward-looking statements.

PDS Biotech Independent Data Monitoring Committee Recommends VERSATILE-002 Trial Continuation without Modifications

Retrieved on: 
Thursday, August 4, 2022
Patient safety, Colon, PR, Fast Track, DMC, 2012 Giro d'Italia, Stage 1 to Stage 11, Goal, Annual general meeting, COVID-19, Breast, Neck, Merck Sharp & Dohme Federal Credit Union, Biotechnology, Pembrolizumab, Merck, Head, ASCO, Risk, Patient, Food, Company, Infection, Review, Survival, Communication, CPI, Sharp, Nasdaq, Safety, Society, Cancer, American Society of Clinical Oncology, Vaccine, Lung, Data monitoring committee, Research, Forward-looking statement, GLOBE, Prostate, Twitter, PDS, Food and Drug Administration Amendments Act of 2007, Nature, Immune system, Toxicity, PDSB, HNSCC, Immunotherapy, SEC, Merck & Co., Pharmaceutical industry

Based on their review of patients with available safety data, PDS0101 in combination with KEYTRUDA continues to appear safe and well tolerated.

Key Points: 
  • Based on their review of patients with available safety data, PDS0101 in combination with KEYTRUDA continues to appear safe and well tolerated.
  • The DMC recommended continuing the trial with no modifications.
  • mentioned Dr. Lauren V. Wood, Chief Medical Officer of PDS Biotech.
  • The safety data in patients with recurrent or metastatic HPV16-positive head and neck cancer continues to appear to be well tolerated.

Prevent Cancer Foundation® awards $250,000 to LGBTQ+ cancer prevention and early detection programs throughout the U.S.

Retrieved on: 
Wednesday, August 3, 2022
People, COVID-19, Attention, Prevalence, Education, American Samoa, Hepatitis B, AOCN, Transgender, Yale New Haven Health System, Cancer, Breast cancer, Foundation, Risk, Washoe people, Breast, Patient navigators, Organization, PAP, DNP, Community, Color, HPV, Research, Gaps, Social media, GLOBE, Partnership, Colorectal cancer, Liver, Cervical cancer, Cirrhosis, Vaccination, CA, Person, Death, Awareness, Liver cancer, LGBTQ, Program, Population, Pharmaceutical industry, Birth control, Vaccine, Medical imaging

These projects will have a direct impact on members of the LGBTQ+ community, many of whom lack access to cancer prevention and early detection services.

Key Points: 
  • These projects will have a direct impact on members of the LGBTQ+ community, many of whom lack access to cancer prevention and early detection services.
  • We are thrilled to be supporting this diverse array of projects that bring attention to cancer screening disparities in the LGBTQ+ community, said Heather Mackey, DNP, ANP-BC, AOCN, Senior Director of Cancer Prevention and Early Detection at the Prevent Cancer Foundation.
  • TheCancer Education and Patient Navigation Programprovides comprehensive cancer education, prevention and early detection support, focused on a community in which cancer is the top cause of death.
  • The Prevent Cancer Foundation is the only U.S. nonprofit organization focused solely on saving lives across all populations through cancer prevention and early detection.

Propanc Biopharma Establishes Joint Research Collaboration Agreement with the Universities of Jaén and Granada

Retrieved on: 
Wednesday, August 3, 2022
Research, General Health, Pharmaceutical, Oncology, Hospitals, Genetics, Clinical Trials, Science, Surgery, Biotechnology, FDA, Health, Intellectual property, Accounting, B cell, University of Granada, Security (finance), University, Recurrence, Brain, Neoplasm, PRP, Growth, OTCQB, Patient, Biomedical Research, Company, Budget, U.S. Securities and Exchange Commission, Trypsinogen, CSCS, FDA, Lung, Bachelor of Medicine, Bachelor of Surgery, Tumor microenvironment, Pancreas, Enzyme, Research, PPCB, Science, Metastasis, Cancer, Prostate, Toxicity, MB, Center, Kidney, Phenotype, Liver, Chymotrypsinogen, Breast, Pharmaceutical industry, Medical imaging

Propanc Biopharma, Inc. (OTCQB: PPCB) (Propanc or the Company), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that a Joint Research Collaboration Agreement has been established with the Universities of Jan and Granada, Spain.

Key Points: 
  • Propanc Biopharma, Inc. (OTCQB: PPCB) (Propanc or the Company), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that a Joint Research Collaboration Agreement has been established with the Universities of Jan and Granada, Spain.
  • The work is being conducted at the laboratory of Professor Macarena Pern PhD, who is the lead researcher on the project and is the second Joint Research Collaboration Agreement currently in progress with the two Spanish Universities.
  • This process of reversing the tumor phenotype, called differentiation, is how proenzymes exert anti-tumor, anti-cancer and anti-metastatic effects.
  • Propanc will own any intellectual property developed during the research, and publishing rights, in exchange for any net future royalties from intellectual property rights.

Dr. Sam Jejurikar Honored Among The Best Plastic Surgeons in America

Retrieved on: 
Wednesday, August 3, 2022
Politics, Plastic surgery, Publication, Skin, Culture, Medicine, Patient, American Medical Association, Education, American Society of Plastic Surgeons, American Board of Plastic Surgery, Health, Industry, Tissue, Society, Microsurgery, Technology, Face, Solution, Plastic, Aesthetic Plastic Surgery, National Society of Certified Healthcare Business Consultants, American Society for Aesthetic Plastic Surgery, Master of Business Administration, Medical missions, MBA, D Magazine, American Board of Commissioners for Foreign Missions, Rhinoplasty, Surgeon, University, Breast, Dentistry, Newsweek

DALLAS, Aug. 3, 2022 /PRNewswire/ -- Upon the release of Newsweek's rankings of America's Best Plastic Surgeons, Dr. Sam Jejurikar of Dallas, Texas, was honored as a top plastic surgeon. Dr. Sam Jejurikar stood out amongst the competition from across the country after a thorough analysis of his track record as an outstanding practitioner.

Key Points: 
  • DALLAS, Aug. 3, 2022 /PRNewswire/ --Upon the release of Newsweek's rankings of America's Best Plastic Surgeons, Dr. Sam Jejurikar of Dallas, Texas, was honored as a top plastic surgeon.
  • Board-certified by the American Board of Plastic Surgery, Dr. Sam Jejurikar has been practicing medicine since 1997.
  • Board-certified plastic surgeon Dr. Sam Jejurikar serves patients in Dallas, Plano, and beyond via the Dallas Plastic Surgery Institute.
  • Dr. Jejurikar is an active member of the American Society of Plastic Surgeons, American Society for Aesthetic Plastic Surgery, Dallas Society of Plastic Surgeons, American Medical Association, and a diplomat of the American Board of Plastic Surgery.

ProfoundBio Receives FDA "Study May Proceed" Letter for PRO1184, a Folate Receptor Alpha-Directed ADC with a Topoisomerase 1 Inhibitor Payload, and Welcomes Naomi Hunder, M.D., as Chief Medical Officer

Retrieved on: 
Wednesday, August 3, 2022
Thomas Jefferson University, Chief executive officer, US FDA, VP, Genetics, Medical Affairs Bureau, CDX, Food, Patient, Therapeutic index, Safety, FDA, Fred Hutchinson Cancer Research Center, Internal medicine, IND, AACR, Seagen, Conjugation, Carleton College, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Pharmacokinetics, Cancer, Research, Therapy, FRA, Doctor of Philosophy, Control, University, Mesothelioma, US, Breast, Pharmaceutical industry, Biology

PRO1184 is an antibody-drug conjugate comprising a folate receptor alpha (FRa) directed antibody conjugated to an exatecan payload with a novel, proprietary hydrophilic linker.

Key Points: 
  • PRO1184 is an antibody-drug conjugate comprising a folate receptor alpha (FRa) directed antibody conjugated to an exatecan payload with a novel, proprietary hydrophilic linker.
  • Additionally, ProfoundBio announced the appointment of Naomi Hunder, M.D., as Chief Medical Officer.
  • "I am thrilled to welcome Dr. Hunder to the ProfoundBio leadership team, especially during this pivotal transition into a clinical-stage oncology company.
  • Dr. Hunder most recently served as Chief Medical Officer of Silverback Therapeutics, a company focused on the advancement of novel immunotherapies.